[Prevention of effort-induced @entity943 using XXXX ].

@entity1 @entity296 @entity308 @entity1855 @entity26 @entity460 @entity943
In this study prophylactic antiarrhythmic effects of @entity1855 on exercise-induced @entity943 were evaluated in a total of 22 @entity1 . All @entity1 displayed frequent and/or complex @entity943 during repeated exercise tests under control conditions. After two control exercise tests, all @entity1 were treated with 120 mg @entity1855 given every 8 h orally for 4 days. On the 3rd and 4th day of treatment the exercise tests were repeated. The results were that @entity1855 caused a significant reduction in the incidence and severity of exercise-induced @entity943 in 13 out of 22 @entity1 . In @entity1 with concomitant significant ST-segment @entity308 , a prophylactic action could be demonstrated in nine out of ten cases. The antiarrhythmic effect was independent of changes in heart rate. In @entity1 with @entity296 , a reduction in myocardial @entity26 consumption and direct electrophysiological effects (suppression of the "slow response" and/or an increase in the resting potential of the " @entity308 fast response") can be discussed as mechanisms of action. Also, a suppression of "triggered activity" or a direct inhibition of adrenergic effects must be considered. According to our results and the literature, @entity460 antagonists ( @entity1855 type) proved to be suitable drugs for the treatment of exercise-induced @entity943 , particularly in @entity1 with concomitant @entity296 .
